MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

FHS
July 25, 2024
4:35 pm

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

MRI innovation to unveil iron homeostasis in the human brain

Researchers demonstrated a MRI method sensitive to the live brain’s iron homeostasis (the r1-r2 extent of relaxation or relaxivity).

September 14, 2023

Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA

All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of

October 30, 2024

Antipsychotics linked to increased behavioral problems in nursing homes

A new study conducted by researchers at the University of Waterloo analyzed data from nearly 500,000 Canadian patients who lived in nursing homes across Canada

December 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.